Regulatory and Ethical Issues in Pediatric Clinical Research: Recommendations From a Panel Discussion
Corresponding Author
Nilima Kshirsagar MD, PhD, FNAS, FNAMS, FRCP (UK), FCP (USA)
President, South Asian Affiliate of ACCP, National Chair in Clinical Pharmacology, Indian Council of Medical Research, Delhi, India
Corresponding Author:
Nilima Kshirsagar, MD, PhD, FNAS, FNAMS, FRCP (UK), FCP (USA), President, South Asian Affiliate of ACCP (SAC-ACCP), National Chair in Clinical Pharmacology, Indian Council of Medical Research, Delhi, India
Email: [email protected]
Search for more papers by this authorSoumya Swaminathan Dip NB/MNAMS, MD, MBBS
Indian Council of Medical Research and Department of Health Research, Delhi, India
Search for more papers by this authorPramod Jog MD, DNB, FIAP
Indian Academy of Pediatrics, Mumbai, India
Search for more papers by this authorSamir Dalwai MD, DCH, DNB, FCPS, LLB
New Horizons Child Developmental Center and Research Foundation, Neuro Developmental Clinic, Lokmanya Tilak, Municipal General (Sion) Hospital and Medical College, Mumbai, India
Search for more papers by this authorRoli Mathur PhD
Indian Council of Medical Research, Mumbai, India
Search for more papers by this authorChandra Shekhar MD, MBBS
Indian Council of Medical Research, Mumbai, India
Search for more papers by this authorBernd Meibohm PhD, FCP, FAAPS
American College of Clinical Pharmacology, Department of Pharmaceutical Sciences, and Research and Graduate Programs, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA
Search for more papers by this authorY. K. Gupta MBBS, MD, FAMS, FNASc, FIPS,FIAN
Department of Pharmacology and All India Institute of Medical Sciences, New Delhi, India
Search for more papers by this authorNusrat Shafiq MD
Department of Pharmacology, PGIMER, Chandigarh, India
Search for more papers by this authorGangadhar Sunkara PhD
Novartis Institute for Biomedical Research, Cambridge, MA, USA
Search for more papers by this authorV. G. Somani PhD, MPharm
Joint Drugs Controller of India, Government of India, New Delhi, India
Search for more papers by this authorPrasad Kulkarni MD, MBBS
Serum Institute of India Pvt Ltd, Pune, India
Search for more papers by this authorBrian Tseng MD, PhD
Pediatric Therapeutic Area in Clinical Development, Novartis, Cambridge, MA, USA
Search for more papers by this authorDhvani Mehta MPhil
Vidhi Centre for Legal Policy, New Delhi, India
Search for more papers by this authorCorresponding Author
Nilima Kshirsagar MD, PhD, FNAS, FNAMS, FRCP (UK), FCP (USA)
President, South Asian Affiliate of ACCP, National Chair in Clinical Pharmacology, Indian Council of Medical Research, Delhi, India
Corresponding Author:
Nilima Kshirsagar, MD, PhD, FNAS, FNAMS, FRCP (UK), FCP (USA), President, South Asian Affiliate of ACCP (SAC-ACCP), National Chair in Clinical Pharmacology, Indian Council of Medical Research, Delhi, India
Email: [email protected]
Search for more papers by this authorSoumya Swaminathan Dip NB/MNAMS, MD, MBBS
Indian Council of Medical Research and Department of Health Research, Delhi, India
Search for more papers by this authorPramod Jog MD, DNB, FIAP
Indian Academy of Pediatrics, Mumbai, India
Search for more papers by this authorSamir Dalwai MD, DCH, DNB, FCPS, LLB
New Horizons Child Developmental Center and Research Foundation, Neuro Developmental Clinic, Lokmanya Tilak, Municipal General (Sion) Hospital and Medical College, Mumbai, India
Search for more papers by this authorRoli Mathur PhD
Indian Council of Medical Research, Mumbai, India
Search for more papers by this authorChandra Shekhar MD, MBBS
Indian Council of Medical Research, Mumbai, India
Search for more papers by this authorBernd Meibohm PhD, FCP, FAAPS
American College of Clinical Pharmacology, Department of Pharmaceutical Sciences, and Research and Graduate Programs, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA
Search for more papers by this authorY. K. Gupta MBBS, MD, FAMS, FNASc, FIPS,FIAN
Department of Pharmacology and All India Institute of Medical Sciences, New Delhi, India
Search for more papers by this authorNusrat Shafiq MD
Department of Pharmacology, PGIMER, Chandigarh, India
Search for more papers by this authorGangadhar Sunkara PhD
Novartis Institute for Biomedical Research, Cambridge, MA, USA
Search for more papers by this authorV. G. Somani PhD, MPharm
Joint Drugs Controller of India, Government of India, New Delhi, India
Search for more papers by this authorPrasad Kulkarni MD, MBBS
Serum Institute of India Pvt Ltd, Pune, India
Search for more papers by this authorBrian Tseng MD, PhD
Pediatric Therapeutic Area in Clinical Development, Novartis, Cambridge, MA, USA
Search for more papers by this authorDhvani Mehta MPhil
Vidhi Centre for Legal Policy, New Delhi, India
Search for more papers by this author
References
- 1Murray S, McKenna L, Pelfrene E, Botgros R. Accelerating clinical drug development for children with tuberculosis Int J Tuberc Lung Dis. 2015; 19(suppl 1) 69–74.
- 2 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional and national age-sex specific all cause and cause specific mortality for 240 causes of death 1990-2013 a systematic analysis for global burden of disease study 2013. Lancet. 2015; 385: 117–171.
- 3 Global Burden of Diseases Paediatric Collaboration, Kyu HH, Pinho C, Wagner JA, et al. Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the global burden of disease 2013 study. JAMA Pediatr. 2016; 170: 267–287.
- 4Davis JM, Turner MA. Global collaboration to develop new and existing drugs for neonates. JAMA Pediatr. 2015; 169: 887–888.
- 5Cuzzolin L, Atzei A, Fanos V. Off label and unlicensed prescribing for newborns and children in different settings: a review of the literature and consideration about drug safety. Expert Opin Drug Saf. 2006; 5: 703–718.
- 6Bellis JR, Kirkham JJ, Thiesen S, et al. Adverse drug reactions and off -label and unlicensed medicines in children: a nested case control study of inpatients in a paediatric hospital. BMCMed. 2013; 11: 238–243.
- 7 Paediatric Science and Research Activities US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/sdu/sdNavigation.cfm. Accessed August 24, 2016.
- 8 Access to Medicines Index. Index2014. www.accesstomedicineindex.org/half-companies-are-developing-medicines-children. Accessed August 24, 2016.
- 9 Access to Medicine Index. New research: promising vaccine. candidates and persistent R & D gaps. www.accesstomedicineindex.org/na-research-promising-vaccine-candidates. Accessed August 24, 2016.
- 10Dunne J, Murphy MD, Rodriquez WJ. The globalization of paediatric clinical trials. Paediatrics. 2012; 130: 1583–1591.
- 11Nachman S, Ahmed A, Amanullath F, et al. Towards early inclusion of children intuberculosis drugs trial: a consensus statement. Lancet Infect Dis. 2015; 15: 711–720.
